Accolade, Inc.

Hello, and thank you for standing by. Welcome to the Accolade First Quarter 2025 Earnings Results Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during this session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. We ask that you limit yourself to one question only. I would now like to turn the call over to Todd Freeman, so you may begin.

Thanks, Operator. Welcome, everyone, to our fiscal first quarter earnings call. With me on the call today are our Chief Executive Officer, Rajiv Singh, and our Chief Financial Officer, Steve Barnes. Before I turn the call over to Rajiv, please note that we'll be discussing certain non-GAAP financial measures that we believe are important when evaluating accolades performance. Details in the relationship between these non-GAAP measures, the most comparable GAAP measures, and the reconciliations thereof can be found in the press release that's posted on our website. Also, please note that certain statements made during this call will be forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause the actual results to accolade different materially from those expressed or implied in this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available on our website. With that, I would just turn the call over to Rajiv. Thank you, John.

We continue to operate in a large market with an opportunity to grow at attractive rates. Customers continue to find tangible value in the services that we deliver. We're the market leader in our category, and our objective is to create long-term value for our customers, partners, employees, and shareholders by adapting our strategy in the best interests of that objective. With that in mind, this quarter, we've adjusted our revenue expectations for the year while maintaining our adjusted EBITDA outlook. Our rationale is simple. We recognize current financial market factors and the need for reliable bottom line earnings forecasts. With today's guidance, we're creating a higher level of certainty on profitability while maintaining an attractive growth rate and the upside for our market. More details on the specifics in Steve's section later in this call. Here's what you should take away from today's call. First, we're de-risking our business while maintaining attractive growth rates in our market. improving sightlines to our profitability objectives, and positioning ourselves well for the long term. Second, by aligning this way, we give ourselves greater certainty on our out-year profitability and cash flows as well. We plan to give you more depth on our long-term plan in an analyst day later this year. Third, the category of personalized healthcare built off of an advocacy platform is now well established in the marketplace. Demand continues to be strong. It is true in every new market. As you pass the point of category creation, market leaders are established with advantage accruing to the leaders. Accolade was the first and only company in our category to reach the public markets. We are now demonstrating scale in growth and profitability that reinforces our standing as a leader in the market moving forward. Establishing a new market and cementing a leadership position in healthcare services is a messy business. And not every company chooses the same path or the same discipline. But history dictates that those companies that choose extraordinary focus on their customers, smart growth tactics, and scalable profitability always emerge as the winners. Finally, as I mentioned earlier, we're in the next stage of building an attractive market. And we're doing so in a period of massive technological innovation. No company is better positioned than Accolade to turn generative artificial intelligence and virtual services like primary care, expert medical opinion, and a trusted partner platform into a mainstay of how health care is delivered in the years ahead. I'll now hand it over to Steve for the financial details, and I'll return shortly for closing remarks.